India Pharma Outlook Team | Wednesday, 28 October 2026
Cancer drugs are facing renewed scrutiny in India as the latest price revisions expose differences between lower-cost generic medicines and expensive patented therapies.
The National Pharmaceutical Pricing Authority (NPPA) has revised maximum retail prices for 543 cancer drug brands and pack sizes under a policy capping trade margins on 137 non-scheduled anti-cancer drugs at 30 percent.
While medicines such as sunitinib and lapatinib have seen substantial price reductions, several prominent branded therapies, including Keytruda and Tagrisso, remain unchanged.
The development raises a broader question: can trade-margin controls meaningfully reduce cancer treatment costs when the prices of expensive medicines remain high?
India’s trade margin rationalization policy targets the difference between the price charged at the first point of sale and the maximum retail price (MRP).
By restricting excessive margins across the distribution chain, the NPPA aims to make selected medicines more affordable without directly imposing a uniform price reduction on every product.
However, branded cancer drugs do not respond uniformly to this mechanism.
Prices of several high-cost originator medicines, including pembrolizumab (Keytruda), osimertinib (Tagrisso) and durvalumab (Imfinzi), have remained unchanged.
Patent protection, competition, manufacturer pricing decisions and the availability of alternative treatments can all influence the final cost.
Where generic competition is limited, reducing distribution margins may not be sufficient to make a high-priced medicine affordable for a wider patient population.
The government has projected annual savings of Rs 2,500 crore from the wider intervention, with the actual reductions varying according to existing price structures.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
The contrast between patented therapies and generic cancer drugs provides a useful way to assess the impact of the policy.
According to the latest reports, the market price of sunitinib is set to fall from Rs 3,942 to Rs 1,520, while a pack of 30 lapatinib tablets is set to decline from Rs 11,870 to Rs 2,354.
Price reductions vary by brand, formulation and pack size, so the impact must be assessed using the notified prices of individual products rather than a single headline percentage.
For cancer drug pricing, this creates two distinct challenges:
The revised prices are scheduled to take effect on November 9, 2026. Their implementation will therefore be a significant test of whether NPPA’s intervention translates into savings for the patients.
The question of affordability of cancer drugs extends beyond their MRP price. Several factors such as dosage frequency, combination therapies, diagnostic monitoring and hospital-based administration can accumulate over the course of treatment.
Useful indicators to evaluate cancer treatment cost include:
The effectiveness of NPPA’s drug price cap will also depend on the compliance of manufacturers, distributors, retailers and hospitals.
The government, on its end, has directed relevant stakeholders to implement the revised prices and maintain supplies of notified formulations. Patients can check the revised prices through the NPPA website and the Pharma Sahi Daam application.
Ultimately, India’s cancer drug price framework needs to focus on tracking actual transaction prices and the complete treatment bills to determine if the latest intervention makes cancer care more affordable in practice.
.jpg)
